​
​

Lumos Pharma Stock (NASDAQ:LUMO)

ForecastRevenueOwnershipFinancialsChartTranscripts
Lumos Pharma by TradingView

Previous Close

$4.33

52W Range

$1.37 - $4.58

50D Avg

$4.04

200D Avg

$2.99

Market Cap

$37.36M

Avg Vol (3M)

$90.78K

Beta

0.33

Div Yield

-

LUMO Company Profile

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

Nov 11, 2011

Website

LUMO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Royalty$2.00M$1.50M$220.00K
License and Service--$10.00K

Fiscal year ends in Dec 23 | Currency in USD

LUMO Financial Summary

Dec 23Dec 22Dec 21
Revenue$2.05M$1.52M$230.00K
Operating Income$-36.61M$-32.04M$-31.35M
Net Income$-34.03M$-31.06M$-30.43M
EBITDA$-36.61M$-32.04M$-31.35M
Basic EPS-$-3.71$-3.65
Diluted EPS-$-3.71$-3.65

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Aug 01, 24 | 9:30 PM
Q1 24May 15, 24 | 12:00 AM
Q4 23Mar 07, 24 | 5:45 PM

Peer Comparison

TickerCompany
IPSCCentury Therapeutics, Inc.
ERASErasca, Inc.
CSBRChampions Oncology, Inc.
RZLTRezolute, Inc.
SILOSilo Pharma, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
PRDSPardes Biosciences, Inc.
FBRXForte Biosciences, Inc.
STTKShattuck Labs, Inc.
ELYMEliem Therapeutics, Inc.